Next Article in Journal
Prostate Magnetic Resonance Imaging Analyses, Clinical Parameters, and Preoperative Nomograms in the Prediction of Extraprostatic Extension
Previous Article in Journal
Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy
Article

COVID-19 in Multimorbid Patients—A Controlled Microcost Description Analysis of Diagnosis Related Group (DRG)-Case Series in Acute Care without Non-Invasive Ventilation

1
Institute for Management and Economics in Healthcare, UMIT Tirol—Private University for Health Sciences, Medical Informatics and Technology, 6060 Hall in Tirol, Austria
2
Waldhausklinik, Acute Hospital for Internal Medicine, Pain Therapy, Complementary and Individualized Patient Centred Medicine, 86391 Deuringen, Germany
*
Author to whom correspondence should be addressed.
Clin. Pract. 2021, 11(4), 755-762; https://doi.org/10.3390/clinpract11040090
Received: 30 July 2021 / Revised: 24 September 2021 / Accepted: 30 September 2021 / Published: 8 October 2021
Diagnosis-related cost analyzes are important for health economic planning and decision-making. They form the basis for further developing of remuneration systems for health services. The rapid increase in hospital stays by COVID-19 patients requires a valid and exact calculation of the treatment costs. COVID-19 patients with many accompanying illnesses increase the requirements for a cost calculation. The focus of this work is to carry out a DRG-related micro-cost analysis, considering the age, length of stay and comorbidities of COVID-19 patients. So far, there is little information about treatment costs for multimorbid patients with COVID-19 who have not received invasive ventilation. The method is based on a standardized cost unit calculation for determining the treatment costs in a German hospital. The costs (€) of inpatients treated with COVID-19 were compared with a control group of the same DRGs of patients without COVID-19. The average total costs for inpatient treatment were €2866. The highest share of costs falls on nursing, personnel, and material costs of the non-medical infrastructure. Frequent comorbidities were heart failure, diabetes mellitus, other respiratory diseases, dizziness, and impairment of the musculoskeletal system. View Full-Text
Keywords: COVID-19; costs; DRG; multimorbidity; LoS; micro-costing COVID-19; costs; DRG; multimorbidity; LoS; micro-costing
Show Figures

Figure 1

MDPI and ACS Style

Romeyke, T.; Stummer, H. COVID-19 in Multimorbid Patients—A Controlled Microcost Description Analysis of Diagnosis Related Group (DRG)-Case Series in Acute Care without Non-Invasive Ventilation. Clin. Pract. 2021, 11, 755-762. https://doi.org/10.3390/clinpract11040090

AMA Style

Romeyke T, Stummer H. COVID-19 in Multimorbid Patients—A Controlled Microcost Description Analysis of Diagnosis Related Group (DRG)-Case Series in Acute Care without Non-Invasive Ventilation. Clinics and Practice. 2021; 11(4):755-762. https://doi.org/10.3390/clinpract11040090

Chicago/Turabian Style

Romeyke, Tobias, and Harald Stummer. 2021. "COVID-19 in Multimorbid Patients—A Controlled Microcost Description Analysis of Diagnosis Related Group (DRG)-Case Series in Acute Care without Non-Invasive Ventilation" Clinics and Practice 11, no. 4: 755-762. https://doi.org/10.3390/clinpract11040090

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop